Abstract
The paper presents the physicochemical and structural characteristics as well as the comparison of selected statins. Statins are relatively popular compounds used in modern medicine. They are increasingly often combined with other medications to improve the effectiveness of therapy. We analyzed the characteristics of pravastatin, simvastatin, atorvastatin, pitavastatin, lovastatin, mevastatin, fluvastatin, and rosuvastatin obtained from the PubChem Substance database. On the basis of data related to chemical structure and physicochemical properties, the statins were grouped into more and less similar ones. Statins are not homogeneous in terms of physicochemical properties and structure. Three groups of statins were identified. Mevastatin, lovastatin, and simvastatin are the most similar to each other, while pravastatin shows a slightly lower similarity to them. Pitavastatin and fluvastatin are also highly similar, while atorvastatin and rosuvastatin, because of their properties, are the most different from other statin groups.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Uniwersytet Jagielloński Collegium Medicum, K/ZDS/006364, Funder Id: 10.13039/100009045, grant no: UMO-2011/01/D/NZ4/03401(K/PBD/000012).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
[1] Bizukojæ M, Ledakowicz S. Biosynteza lowastatyny przez Aspergillus terreus. Biotechnologia Monografie 2005;2:55–67.Search in Google Scholar
[2] Sirtori CR. The pharmacology of statins. Pharmacol Res 2014;88:3–11.10.1016/j.phrs.2014.03.002Search in Google Scholar PubMed
[3] Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A. Adverse effects of statins – mechanisms and consequences. Curr Drug Saf 2009;4:209–28.10.2174/157488609789006949Search in Google Scholar PubMed
[4] Awad K, Banach M. The optimal time of day for statin administration: a review of current evidence. Curr Opin Lipidol 2018;29:340–5.10.1097/MOL.0000000000000524Search in Google Scholar PubMed
[5] Awad K, Serban M-C, Penson P, Mikhailidis DP, Toth PP, Jones SR, et al. Effects of morning vs evening statin administration on lipid profile: a systematic review and meta-analysis. J Clin Lipidol 2017;11:972–85.s.10.1016/j.jacl.2017.06.001Search in Google Scholar PubMed
[6] Plakogiannis R, Cohen H. Optimal low-density lipoprotein cholesterol lowering – morning versus evening statin administration. Ann Pharmacother 2007;41:106–10.10.1345/aph.1G659Search in Google Scholar PubMed
[7] Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res 2016;44:D1202–13.10.1093/nar/gkv951Search in Google Scholar PubMed PubMed Central
[8] Schrödinger L. PyMOL: the PyMOL molecular graphics system. New York: Schrödinger, LLC, 2018.Search in Google Scholar
[9] Cao Y, Charisi A, Cheng L-C, Jiang T, Girke T. ChemmineR: a compound mining framework for R. Bioinformatics 2008;24:1733–4.10.1093/bioinformatics/btn307Search in Google Scholar PubMed PubMed Central
[10] Bader RF. Bond paths are not chemical bonds. J Phys Chem A 2009;113:10391–6.10.1021/jp906341rSearch in Google Scholar PubMed
[11] Holliday JD, Salim N, Whittle M, Willett P. Analysis and display of the size dependence of chemical similarity coefficients. J Chem Inf Comput Sci 2003;43:819–28.10.1021/ci034001xSearch in Google Scholar PubMed
[12] Cao Y, Jiang T, Girke T. A maximum common substructure-based algorithm for searching and predicting drug-like compounds. Bioinformatics. Oxford: Oxford University Press, 2008.10.1093/bioinformatics/btn186Search in Google Scholar PubMed PubMed Central
[13] Maggiora G, Vogt M, Stumpfe D, Bajorath J. Molecular similarity in medicinal chemistry. J Med Chem 2014;57:3186–204.10.1021/jm401411zSearch in Google Scholar PubMed
[14] Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.10.1056/NEJM199811053391902Search in Google Scholar PubMed
[15] Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–9.10.1056/NEJM199610033351401Search in Google Scholar PubMed
[16] Carter NJ. Rosuvastatin. Am J Cardiovasc Drug 2010;10:383–400.10.2165/11204600-000000000-00000Search in Google Scholar PubMed
©2018 Walter de Gruyter GmbH, Berlin/Boston
